Last quarter (Q4 2022), Amplia Therapeutics Ltd.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Amplia Therapeutics Ltd.'s net income was $―. See Amplia Therapeutics Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 5.63M	$ 3.87M	$ 2.26M	$ 1.94M	$ 4.97M
Operating Income	$ ―	$ -5.63M	$ -3.87M	$ -2.26M	$ -1.94M	$ -4.97M
Net Non Operating Interest Income Expense	$ ―	$ -534.00	$ 1.29K	$ 3.72K	$ 20.28K	$ 26.97K
Other Income Expense	$ ―	$ 1.98M	$ 1.59M	$ 34.23K	$ 50.47K	$ 642.84K
Pretax Income	$ ―	$ -3.64M	$ -2.28M	$ -2.22M	$ -1.87M	$ -4.30M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -3.64M	$ -2.28M	$ -2.22M	$ -1.87M	$ -4.30M
Basic EPS	$ ―	$ -0.03	$ -0.02	$ -0.04	$ -0.04	$ -0.19
Diluted EPS	$ ―	$ -0.03	$ -0.02	$ -0.04	$ -0.04	$ -0.19
Basic Average Shares	$ ―	$ 145.55M	$ 95.70M	$ 52.96M	$ 42.98M	$ 22.56M
Diluted Average Shares	$ ―	$ 145.55M	$ 95.70M	$ 52.96M	$ 42.98M	$ 22.56M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -3.64M	$ -2.28M	$ -2.22M	$ -1.87M	$ -4.30M
Normalized Income	$ ―	$ -3.64M	$ -2.28M	$ -2.22M	$ -1.87M	$ -4.30M
Interest Expense	$ ―	$ 1.15K	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ -3.64M	$ -3.87M	$ -2.26M	$ -1.94M	$ -4.97M
EBITDA	$ ―	$ -3.64M	$ -3.87M	$ -2.26M	$ -1.94M	$ -4.95M

Currency in USD

Amplia Therapeutics Ltd. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing